Table 3.

Major treatment-related adverse events, n (%)

Adverse events	Grade 1–2, n (%)	Grade 3, n (%)	Grade 4, n (%)	Grade 5, n (%)	ALL, n (%)
Non-hematologic
Hypertension	23 (45.10)	3 (5.88)	3 (5.88)	0	29 (56.86)
Hand–foot syndrome	25 (49.02)	2 (3.92)	0	0	27 (52.94)
Proteinuria	24 (47.06)	1 (1.96)	0	0	25 (49.02)
Mucositis	10 (19.61)	0	0	0	10 (19.61)
Fatigue	18 (35.29)	1 (1.96)	1 (1.96)	0	20 (39.22)
Myalgia/arthralgia	5 (9.80)	0	0	0	5 (9.80)
Hyperbilirubinemia	1 (1.96)	0	0	0	1 (1.96)
Aminotransferase increased	2 (3.92)	0	0	0	2 (3.92)
Vomiting	9 (17.65)	1 (1.96)	0	0	10 (19.61)
Erythra	2 (3.92)	0	0	0	2 (3.92)
Nausea	7 (13.73)	1 (1.96)	0	0	8 (15.69)
Headache	6 (11.76)	2 (3.92)	0	0	8 (15.69)
Pain	3 (5.88)	0	0	0	3 (5.88)
Alopecia	2 (3.92)	0	0	0	2 (3.92)
hemorrhage	7 (13.73)	0	2 (3.92)	0	9 (17.65)
Hematologic
Leucopenia	7 (13.73)	0	0	0	7 (13.73)
Neutropenia	18 (35.29)	1 (1.96)	0	0	19 (37.25)
Thrombocytopenia	6 (11.76)	0	0	0	6 (11.76)
Anemia	15 (29.41)	1 (1.96)	1 (1.96)	0	17 (33.33)